Literature DB >> 18560751

Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan.

Yasuhito Nannya1, Hiromitsu Yokota2, Yumiko Sato2, Go Yamamoto1, Takashi Asai1, Motoshi Ichikawa1, Takuro Watanabe1, Keiki Kumano1,3, Akira Hangaishi1, Tsuyoshi Takahashi1, Shigeru Chiba3, Yutaka Yatomi2, Mineo Kurokawa4,5.   

Abstract

We retrospectively analyzed the clinical outcome of chronic myelogenous leukemia (CML) patients who received imatinib mesylate (IM) as initial therapy at Tokyo University Hospital. In all patients, molecular response as well as hematological and cytogenetic response was measured routinely. Our cohort showed respectable outcome with complete cytogenetic response (CR) of 82% in 1 year, and 97% in 5 years. The estimated progression free survival of 29 patients who were in chronic phase at diagnosis was 97% and the estimated OS was 92.4% at 5 years. Although IM interruption due to side effects was observed in about half of the cases, the discontinuation was only temporary in all cases. However, patients who showed persistent intolerance with adequate dose of IM (300 mg/day or more) showed poor molecular response.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18560751     DOI： 10.1007/s12185-008-0111-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  15 in total

Review 1.  Chronic myeloid leukemia.

Authors:  C L Sawyers
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

2.  Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.

Authors:  M Emig; S Saussele; H Wittor; A Weisser; A Reiter; A Willer; U Berger; R Hehlmann; N C Cross; A Hochhaus
Journal:  Leukemia       Date:  1999-11       Impact factor: 11.528

Review 3.  An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.

Authors:  R T Silver; S H Woolf; R Hehlmann; F R Appelbaum; J Anderson; C Bennett; J M Goldman; F Guilhot; H M Kantarjian; A E Lichtin; M Talpaz; S Tura
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

4.  Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

Authors:  Francois Guilhot; Jane Apperley; Dong-Wook Kim; Eduardo O Bullorsky; Michele Baccarani; Gail J Roboz; Sergio Amadori; Carmino A de Souza; Jeffrey H Lipton; Andreas Hochhaus; Dominik Heim; Richard A Larson; Susan Branford; Martin C Muller; Prasheen Agarwal; Ashwin Gollerkeri; Moshe Talpaz
Journal:  Blood       Date:  2007-01-30       Impact factor: 22.113

Review 5.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Authors:  Michele Baccarani; Giuseppe Saglio; John Goldman; Andreas Hochhaus; Bengt Simonsson; Frederick Appelbaum; Jane Apperley; Francisco Cervantes; Jorge Cortes; Michael Deininger; Alois Gratwohl; François Guilhot; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Dietger Niederwieser; Richard Silver; Rudiger Hehlmann
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

6.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

7.  Selection of an internal control gene for quantitation of mRNA in colonic tissues.

Authors:  Naoki Tsuji; Chinatsu Kamagata; Momoko Furuya; Daisuke Kobayashi; Atsuhito Yagihashi; Takayuki Morita; Shoichi Horita; Naoki Watanabe
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

Review 8.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Authors:  Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

9.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Authors:  Tim P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee L Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich
Journal:  N Engl J Med       Date:  2003-10-09       Impact factor: 91.245

10.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Authors:  Hagop M Kantarjian; Francis Giles; Norbert Gattermann; Kapil Bhalla; Giuliana Alimena; Francesca Palandri; Gert J Ossenkoppele; Franck-Emmanuel Nicolini; Stephen G O'Brien; Mark Litzow; Ravi Bhatia; Francisco Cervantes; Ariful Haque; Yaping Shou; Debra J Resta; Aaron Weitzman; Andreas Hochhaus; Philipp le Coutre
Journal:  Blood       Date:  2007-08-22       Impact factor: 22.113
View more
  2 in total

1.  Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia.

Authors:  Yanmin Zhao; Yamin Tan; Gongqiang Wu; Lizhen Liu; Yingjia Wang; Yi Luo; Jimin Shi; He Huang
Journal:  Int J Hematol       Date:  2011-07-05       Impact factor: 2.490

2.  Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population.

Authors:  Yanmin Zhao; Lizhen Liu; Yingjia Wang; Gongqiang Wu; Xiaoyu Lai; Weijie Cao; Yi Luo; Yamin Tan; Jimin Shi; Wanzhuo Xie; Xiujin Ye; Zhen Cai; Maofang Lin; He Huang
Journal:  Int J Hematol       Date:  2009-04-07       Impact factor: 2.490
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.